Taylor RS, Drummond MF, Salkeld G, Sullivan SD (2004) Inclusion of cost effectiveness in Veliparib datasheet licensing requirements of new drugs: the fourth hurdle. BMJ 329:972–5PubMedCrossRef 17. Drummond M, Dubois D, Garattini L et al (1999) Current trends in the use of pharmacoeconomics and outcomes research in europe. Value Health 2:323–32PubMedCrossRef 18. Hiligsmann M, Ethgen O, Bruyere O, Richy F, Gathon HJ, Reginster JY (2009) Development and validation of a Markov microsimulation model for the economic click here evaluation of treatments in osteoporosis. Value Health 12:687–96PubMedCrossRef 19. Hiligsmann M, Gathon HJ, Bruyere O, Ethgen O, Rabenda V, Reginster

JY (2010) Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health 13:394–401PubMedCrossRef 20. Hiligsmann M, Rabenda V, Bruyere O, Reginster JY (2010) The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy 96:170–7PubMedCrossRef 21. Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 86:202–10CrossRef 22. Hiligsmann M, Reginster JY (2010) Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. Bone 47:34–40PubMedCrossRef 23. Hiligsmann M, Reginster

JY (2011) Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal

this website osteoporotic women in belgium. PharmacoEconomics 29:895–911PubMedCrossRef 24. Johansson H, Kanis JA, McCloskey EV et al (2011) A FRAX(R) model for the assessment of fracture probability in Belgium. Osteoporos Int 22:453–61PubMedCrossRef 25. Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417–27PubMedCrossRef 26. Johnell O, Kanis JA, Oden A et al (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38–42PubMedCrossRef 27. PRKD3 Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15:108–12PubMedCrossRef 28. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468–73PubMedCrossRef 29. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. Osteoporos Int 11:556–61PubMedCrossRef 30. Tosteson AN, Jonsson B, Grima DT, O’Brien BJ, Black DM, Adachi JD (2001) Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 12:849–57PubMedCrossRef 31. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15:108–12PubMedCrossRef 32.